The cornerstone of the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center is the Translational Therapeutics. The program directed by Dr. Michael Vogelbaum, aggressive pre-clinical testing of the most promising anti-cancer agents is underway. One goal is to accelerate the lengthy and expensive process of testing new drugs targeted against brain tumors and to safely move them into clinical trials as quickly as possible, for the benefit of patients.
Physicians, researchers and scientists involved in this area work with both pharmaceutical companies and other medical institutions to identify, obtain and test new compounds. The Burkhardt Brain Tumor Center's multi-million dollar efforts, including an international search for all potential brain tumor-relevant therapies, have yielded several promising agents for testing.
Testing of new agents involves evaluating the toxicity and efficacy of these compounds in the laboratory and in animals that have brain tumors. In addition, we are also investigating the optimal route of delivery of these drugs.
Because many of new therapeutic agents cannot penetrate the central nervous system, researchers are exploring alternative delivery methods. In addition to investigating the efficacy of oral delivery, researchers evaluate the efficacy of the agents when delivered intracerebrally-directly into the brain-via a specialized neurosurgical technique called convection enhanced delivery (CED).
The staff is focused on translating these pre-clinical results into Phase I and II clinical trials - giving the brain tumor patient more therapeutic treatment options by broadening the horizon of potential tools we may use to manage this deadly disease.
Our Center for Translational Therapeutics has started research projects with a number of pharmaceutical and biotechnology companies, ranging in size from small startup firms to some of the largest publicly traded companies. What these companies have in common are novel drugs that are close to or in clinical trial and which are rationally designed to be effective against malignant gliomas given the molecular and genetic makeup of these tumors.
To schedule an evaluation with a Burkhardt Brain Tumor Center specialist, please call our Appointment Center at 216.636.5860 or toll-free at 866.588.2264.